Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 101–200 of 1,000
Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30106-2 · Cited by 216
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., Fargnoli, M. C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.015 · Cited by 213
“Ipilimumab is approved for melanoma therapy by the FDA and EMA.”
BackgroundMethodInfluentialSelf-citationImmune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC: CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 205
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 199
Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance Fernandez, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3145 · Cited by 198
“Statistical tests for efficacy analyses are described in the Supplementary material and have also been published previously (3).”
InfluentialSelf-citationTargeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205
Dreno, B., Thompson, J. F., Smithers, B. M., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P., Grob, J.-J., Korovin, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30254-7 · Cited by 205
Self-citationMelanoma models for the next generation of therapies
Patton, E. E., Mueller, K. L., Adams, D. J., Anandasabapathy, N., Aplin, A. E., Bertolotto, C., Bosenberg, M., Ceol, C. J., Burd, C. E., Chi, P., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.011 · Cited by 206
“Approvals of targeted and immuno-therapies for patients with stage III operable melanomas (adjuvant therapy), have further extended the number of patients who can benefit from these therapeutic advances (Eggermont et al., 2018; Long et al., 2017; Robert et al., 2019; Weber et al., 2017).”
BackgroundMountzios, G., Remon, J., Hendriks, L. E. L., García-Campelo, R., Rolfo, C., Van Schil, P., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 199
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Jiang, S., Liu, Y., Zheng, H., Zhang, L., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000492 · Cited by 189
“Of these, three studies focused on the application of ICIs in neoadjuvant immunotherapy([14,15,23]), and two discussed the application of ICIs in adjuvant therapy([50,51]).”
BackgroundIndini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F., & Del Vecchio, M. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2819-x · Cited by 202
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P., Heeke, S., Alix-Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 200
Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
Oliveira, A. F., Bretes, L., & Furtado, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00396 · Cited by 198
“Adjuvant ipilimumab or nivolumab have shown to extend survival in stage III or IV (resected) but mechanisms of resistance in CRCs in this setting are not necessarily the overexpression of immune checkpoints (34).”
BackgroundYang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
Meraz-Muñoz, A., Amir, E., Ng, P., Avila-Casado, C., Ragobar, C., Chan, C., Kim, J., Wald, R., & Kitchlu, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000467 · Cited by 194
Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02574-0 · Cited by 193
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S., Nimeiri, H., Fought, A. J., Benson, A., & Mulcahy, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 194
Tang, S.-Q., Tang, L.-L., Mao, Y.-P., Li, W.-F., Chen, L., Zhang, Y., Guo, Y., Liu, Q., Sun, Y., Xu, C., et al. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.790 · Cited by 192
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O., Stern, M.-H., Pierga, J.-Y., & Bidard, F.-C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 196
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz048 · Cited by 186
“Eighteen (14%) patients participated on an adjuvant immune checkpoint inhibitor clinical trial [7, 9] Somatic mutation testing was performed in 126/133 individuals due to availability of primary tumor tissue and identified at least one somatic mutation in 99/126 (79%) patients.”
BackgroundTumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy
Buchwald, Z. S., Nasti, T. H., Lee, J., Eberhardt, C. S., Wieland, A., Im, S. J., Lawson, D., Curran, W., Ahmed, R., & Khan, M. K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000867 · Cited by 183
“33 34 The landmark PACIFIC Trial which showed an overall survival benefit for adjuvant durvalumab ( α PD-L1) following definitive chemoradiation for Stage III non-small cell lung cancer is one of the first trials to incorporate both radiation and checkpoint blockade in the stage III setting.”
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.001 · Cited by 182
Self-citationKomiya, T., & Huang, C. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00423 · Cited by 186
“In early-stage disease, a phase I/IIb trial is ongoing to assess the safety, toxicity, and PFS in patients who had undergone maximum debulking surgery for ovarian cancer using E (63) based on the improvement of recurrencefree survival using P/N as adjuvant therapy in resectedmelanoma (64, 65) and durvalumab in stage I…”
MethodTarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01381 · Cited by 184
“After the activation of E1609, the CheckMate-238 study demonstrated RFS benefit with adjuvant nivolumab versus ipi10.(6) Significant RFS benefits versus placebo were reported for pembrolizumab in KeyNote-054 and the combination of dabrafenib and trametinib in patients with BRAF-mutated melanoma in COMBI-AD.”
ResultThe Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
“Severe irAEs (grade ≥3) have occurred in 28–56% and 21–32% in patients treated with ipilimumab or anti-PD-1/anti-PD-L1 antibodies, respectively (10, 12, 16, 162, 163).”
BackgroundAutio, K. A., Boni, V., Humphrey, R. W., & Naing, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1457 · Cited by 184
The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe
Dimitriou, F., Krattinger, R., Ramelyte, E., Barysch, M. J., Micaletto, S., Dummer, R., & Goldinger, S. M. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0732-8 · Cited by 179
Wong, P. F., Wei, W., Smithy, J. W., Acs, B., Toki, M. I., Blenman, K. R. M., Zelterman, D., Kluger, H. M., & Rimm, D. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2652 · Cited by 182
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00533 · Cited by 173
“Median monotherapy doses were comparable,(2) and flat-dose nivolumab is equivalent to the weight-based dose used in CheckMate 238.(2,7) The consistent results with nivolumab monotherapy in this study and CheckMate 238 suggest that including patients without CLND did not affect RFS.”
MethodResultSelf-citationNiu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Lo, S. N., Ma, J., Scolyer, R. A., Haydu, L. E., Stretch, J. R., Saw, R. P. M., Nieweg, O. E., Shannon, K. F., Spillane, A. J., Ch’ng, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02362 · Cited by 168
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 170
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R.-I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab430 · Cited by 168
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 169
“Nevertheless, adjuvant ICI in resected melanoma is tolerable and has improved DFS.(169) Ongoing”
BackgroundInfluentialNewell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164
Self-citationPreserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
Liu, Y., & Zheng, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.003 · Cited by 162
“[40] reported that, in a large clinical trial involving 906 patients with resected stage III and IV melanoma, patients receiving monotherapy with Nivolumab showed 70.”
BackgroundFive-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Khattak, A., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200214 · Cited by 160
Self-citationQuatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 158
“Melanoma nivolumab/pembrolizumab I and II line [80,94–96]; adjuvant after complete resection [97,98]”
BackgroundTargeted Therapy and Immunotherapy for Melanoma in Japan
Namikawa, K., & Yamazaki, N. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0607-8 · Cited by 159
Self-citationThe Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Sasso, J. M., Tenchov, R., Bird, R. E., Iyer, K. A., Ralhan, K., Rodríguez, Y., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00374 · Cited by 176
Cutaneous Melanoma—A Review in Detection, Staging, and Management
Hartman, R. I., & Lin, J. Y. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.09.005 · Cited by 167
Long, G. V., Luke, J. J., Khattak, M. A., de la Cruz‐Merino, L., Vecchio, M. D., Rutkowski, P. L., Spagnolo, F., Mackiewicz, J., Chiarion‐Sileni, V., Kirkwood, J. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00559-9 · Cited by 160
Self-citationAnti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
Gellrich, F. F., Schmitz, M., Beissert, S., & Meier, F. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010223 · Cited by 165
“In the phase III CheckMate 238 trial [37], patients who had undergone complete resection of locoregional or distant metastases were treated with anti-PD-1 nivolumab or anti-CTLA-4 ipilimumab for one year.”
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Long, G. V., Hauschild, A., Santinami, M., Kirkwood, J. M., Atkinson, V. G., Mandalà, M., Merelli, B., Chiarion‐Sileni, V., Nyakas, M., Haydon, A. M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404139 · Cited by 155
Self-citationLugowska, I. A., Teterycz, P., & Rutkowski, P. L. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73889 · Cited by 171
“The first data presented in 2017 showed, that nivolumab administered in patients with melanoma after lymphadenectomy (IIIB, IIIC and IV Stage) is related to the 10% of RFS improvement with lower toxicity as compared with ipilimumab [29].”
ResultSelf-citationZhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N., & Neilan, T. G. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 141
Cancer-associated fibroblasts: how do they contribute to metastasis?
Kwa, M. Q., Herum, K. M., & Brakebusch, C. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09959-0 · Cited by 169
Dimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C., Zichlin, M. L., Brun, A., Signorovitch, J. E., Makenbaeva, D., Mekan, S., Sy, O., et al. (2018) · Cancer · doi:10.1002/cncr.31680 · Cited by 141
“Anemia 309 (97) 64 (20) 301 (95) 68 (21)”
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
van Willigen, W. W., Bloemendal, M., Gerritsen, W. R., Schreibelt, G., de Vries, I. J. M., & Bol, K. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02265 · Cited by 150
“In addition, both nivolumab and pembrolizumab have shown to increase PFS in the adjuvant setting for melanoma (19, 20).”
BackgroundVersluis, J. M., Menzies, A. M., Sikorska, K., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Eriksson, H., Klop, W. M. C., Ch’ng, S., van Thienen, J. V., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.004 · Cited by 151
Self-citationCheckpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Tsang, V. H. M., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00423 · Cited by 139
Self-citationFrench Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Heymach, J. V., Krilov, L., Alberg, A. J., Baxter, N. N., Chang, S. M., Corcoran, R. B., Dale, W., DeMichele, A. M., Diefenbach, C., Dreicer, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0446 · Cited by 167
Considerations for treatment duration in responders to immune checkpoint inhibitors
Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001901 · Cited by 137
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 152
Arance, A. M., de la Cruz‐Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez‐Rodas, I., Spreafico, A., Atkinson, V. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00221 · Cited by 146
Self-citationSarkar, R. R., Gloude, N. J., Schiff, D. E., & Murphy, J. D. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy193 · Cited by 132
“therapy, oncology as a whole represents one of the fastest growing sectors of health-care spending (50), with costly immunotherapy drugs recently becoming first-line standard of care in the management of several common cancers (51,52).”
BackgroundPD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 153
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 169
“Adjuvant therapy (targeting residual disease after surgery) with anti-PD1 is approved and should be considered for patients with resected stage IIb or IIc to stage IV melanoma, independent of BRAF mutation status 163–166 .”
Self-citationCurrent status of immune checkpoint inhibition in early-stage NSCLC
Vansteenkiste, J., Wauters, E., Reymen, B. J. T., Ackermann, C. J., Peters, S., & Ruysscher, D. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz175 · Cited by 145
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 145
Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C., Park, J. J., Spain, L., Turajlic, S., Ardolino, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.017 · Cited by 129
Self-citationDzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 127
Kulkarni, P. M., Robinson, E. J., Sarin Pradhan, J., Gartrell-Corrado, R. D., Rohr, B. R., Trager, M. H., Geskin, L. J., Kluger, H. M., Wong, P. F., Acs, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1495 · Cited by 124
“Effective adjuvant therapy, however, was not introduced into general practice until 2017 with the FDA approval of nivolumab for resected stage III melanoma (24).”
BackgroundGowen, M. F., Giles, K. M., Simpson, D., Tchack, J., Zhou, H., Moran, U., Dawood, Z., Pavlick, A. C., Hu, S., Wilson, M. A., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1452-4 · Cited by 125
“bladder, lung), and in the adjuvant setting for stage III/IV melanoma [6, 7].”
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 149
Du, X., Liu, M., Su, J., Zhang, P., Tang, F., Ye, P., Devenport, M., Wang, X., Zhang, Y., Liu, Y., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0012-z · Cited by 123
Combatting Mucosal Melanoma: Recent Advances and Future Perspectives
Tyrrell, H. E. J., & Payne, M. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0003 · Cited by 138
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 150
“[63] Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al.”
BackgroundKuklinski, L. F., Yan, S., Li, Z., Fisher, J. L., Cheng, C., Noelle, R. J., Angeles, C. V., Turk, M. J., & Ernstoff, M. S. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2169-1 · Cited by 128
BRAF Gene and Melanoma: Back to the Future
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 131
“In the Phase 3 CheckMate-238 trial comparing nivolumab with ipilimumab or placebo as adjuvant therapy, the nivolumab arm showed significantly longer RFS and better safety profile than adjuvant therapy with ipilimumab, regardless of BRAF status [80].”
BackgroundMethodWang, K., Coutifaris, P., Brocks, D., Wang, G., Azar, T., Solis, S., Nandi, A., Anderson, S., Han, N. A., Manne, S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.007 · Cited by 135
Self-citationOncolytic viruses: overcoming translational challenges
Martínez‐Quintanilla, J., Seah, I. Y. J., Chua, M. M. J., & Shah, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122287 · Cited by 130
Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients
Wohlmuth, C., Wieser, I., May, T., Vicus, D., Gien, L. T., & Laframboise, S. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00487-x · Cited by 119
Surgery-mediated tumor-promoting effects on the immune microenvironment
Cheng, X., Zhang, H., Hamad, A., Huang, H., & Tsung, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.006 · Cited by 135
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 122
Self-citationChang, C., Park, H., Malone, D. C., Wang, C.-Y., Wilson, D. L., Yeh, Y., van Boemmel-Wegmann, S., & Lo-Ciganic, W.-H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1611 · Cited by 120
Michielin, O. A., van Akkooi, A. C. J., Lorigan, P. C., Ascierto, P. A., Dummer, R., Robert, C., Arance, A. M., Blank, C. U., Chiarion‐Sileni, V., Donia, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.005 · Cited by 130
Self-citationImmune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 133
Garbe, C., Keim, U., Amaral, T. M. S., Berking, C., Eigentler, T., Flatz, L., Gesierich, A., Leiter, U., Stadler, R., Sunderkötter, C. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00202 · Cited by 120
Self-citationLivingstone, E., Zimmer, L., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F. E., Mohr, P., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01654-3 · Cited by 127
Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 128
Fujisawa, Y., Yoshikawa, S., Minagawa, A., Takenouchi, T., Yokota, K., Uchi, H., Noma, N., Nakamura, Y., Asai, J., Kato, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2110 · Cited by 122
Self-citationRefining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives
Taïeb, J., André, T., & Auclin, É. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.02.002 · Cited by 122
van Holstein, Y., Kapiteijn, E., Bastiaannet, E., van den Bos, F., Portielje, J. E. A., & de Glas, N. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00697-2 · Cited by 116
Evolving impact of long-term survival results on metastatic melanoma treatment
Michielin, O. A., Atkins, M. B., Koon, H. B., Dummer, R., & Ascierto, P. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000948 · Cited by 125
Self-citationAdjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T.-G., Khushalani, N. I., Cohen, J. V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1141 · Cited by 111
Self-citationManagement of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V. G., Zaman, F. Y., Young, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.471 · Cited by 113
Self-citationTiming of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, J., O’Donnell, J. S., Yan, J., Madore, J., Allen, S., Smyth, M. J., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581530 · Cited by 113
“In addition, it was reported that amongst patients with stage IIIB, IIIC, or IV melanoma, the use of adjuvant anti-PD-1 compared to antiCTLA4 resulted in a significantly longer recurrence-free survival (RFS) at 12 months and a better safety profile.(5) Although promising, there is scope to further improve clinical out…”
BackgroundHo, T. T. B., Nasti, A., Seki, A., Komura, T., Inui, H., Kozaka, T., Kitamura, Y., Shiba, K., Yamashita, T., Yamashita, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001367 · Cited by 112
Richtig, G., Hoeller, C., Wolf, M., Wolf, I., Rainer, B. M., Schulter, G., Richtig, M., Grübler, M. R., Gappmayer, A., Haidn, T., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204729 · Cited by 112
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 117
“…(range) time to ICI-P onset was 15.1 (2.6 – 85.1) weeks, 31.1 (11.7 – 56.9) weeks and 7.8 (3.1 – 48.1) weeks in patients receiving nivolumab for advanced squamous cell carcinoma (n=6) [8], advanced nonsquamous cell carcinoma (n=10) [7] and adjuvant melanoma treatment (n=6) [34], respectively.”
BackgroundInfluentialMonoclonal Antibodies: Past, Present and Future
Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 130
The Treatment of Advanced Melanoma: Therapeutic Update
Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., & Scalvenzi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126388 · Cited by 138
“As regards adjuvant treatment, CHECKMATE-238, a randomized, double-blind, randomized (1:1) study, which enrolled 906 patients receiving 3 mg/kg of nivolumab Q2W or ipilimumab 10 mg/kg Q3W in four doses every 12 weeks [24,29,30].”
MethodMelanoma pathology reporting and staging
Scolyer, R. A., Rawson, R. V., Gershenwald, J. E., Ferguson, P. M., & Prieto, V. G. (2019) · Modern Pathology · doi:10.1038/s41379-019-0402-x · Cited by 111
Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
Broderick, S. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.001 · Cited by 113
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.